Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Equity Average (2020 - 2025)

Goldenwell Biotech (GWLL) has disclosed Equity Average for 6 consecutive years, with -$90830.5 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 887.6% year-over-year to -$90830.5, compared with a TTM value of -$90830.5 through Sep 2025, down 887.6%, and an annual FY2024 reading of $18741.0, down 86.91% over the prior year.
  • Equity Average was -$90830.5 for Q3 2025 at Goldenwell Biotech, down from -$84228.0 in the prior quarter.
  • Across five years, Equity Average topped out at $360802.0 in Q2 2021 and bottomed at -$90830.5 in Q3 2025.
  • Average Equity Average over 5 years is $144219.9, with a median of $154470.5 recorded in 2023.
  • The sharpest move saw Equity Average skyrocketed 43.46% in 2021, then crashed 887.6% in 2025.
  • Year by year, Equity Average stood at $316483.5 in 2021, then tumbled by 30.71% to $219284.0 in 2022, then plummeted by 56.62% to $95122.5 in 2023, then plummeted by 114.72% to -$14001.0 in 2024, then plummeted by 548.74% to -$90830.5 in 2025.
  • Business Quant data shows Equity Average for GWLL at -$90830.5 in Q3 2025, -$84228.0 in Q2 2025, and -$64429.5 in Q1 2025.